Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics' Initiates SYN-010 Phase 2 Clinical Trial to Treat Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire June 29, 2015

First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile

PR Newswire June 12, 2015

Synthetic Biologics Presents Initial Data Validating Platform Expansion to Cover Carbapenem Antibiotics

PR Newswire June 3, 2015

Synthetic Biologics Expands Clinical & Regulatory Leadership Team with Addition of Klaus Gottlieb, MD, FACG

PR Newswire June 2, 2015

Synthetic Biologics to Host Microbiome Analyst & Investor Meeting

PR Newswire June 1, 2015

Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted in Late-Breaking Poster at Digestive Disease Week® 2015

PR Newswire May 19, 2015

Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week® Poster

PR Newswire May 18, 2015

Synthetic Biologics Reports First Quarter 2015 Financial Results and Operational Highlights

PR Newswire May 11, 2015

Maureen Early Named Vice President, Commercial of Synthetic Biologics

PR Newswire May 7, 2015

Steven Shallcross Named Chief Financial Officer of Synthetic Biologics

PR Newswire May 4, 2015

Synthetic Biologics to Host First Quarter 2015 Investor Conference Call

PR Newswire April 30, 2015

Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)

PR Newswire April 27, 2015

Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015

PR Newswire April 1, 2015

Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile

PR Newswire March 30, 2015

Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

PR Newswire March 19, 2015

Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights

PR Newswire March 16, 2015

Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015

PR Newswire March 11, 2015

Synthetic Biologics to Report Year End 2014 Financial Results

PR Newswire March 9, 2015

Synthetic Biologics to Present at the 27th Annual ROTH Conference

PR Newswire March 3, 2015

Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015

PR Newswire March 2, 2015